Immatics (NASDAQ:IMTX) Shares Bought by T. Rowe Price Investment Management Inc.

T. Rowe Price Investment Management Inc. increased its stake in Immatics (NASDAQ:IMTX) by 43.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 10,604,777 shares of the company’s stock after purchasing an additional 3,225,141 shares during the quarter. T. Rowe Price Investment Management Inc. owned about 8.88% of Immatics worth $75,400,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of IMTX. State Street Corp lifted its stake in shares of Immatics by 11.2% in the 3rd quarter. State Street Corp now owns 225,202 shares of the company’s stock worth $2,570,000 after acquiring an additional 22,710 shares during the period. abrdn plc lifted its position in Immatics by 49.2% in the fourth quarter. abrdn plc now owns 347,379 shares of the company’s stock worth $2,470,000 after purchasing an additional 114,479 shares during the period. Y Intercept Hong Kong Ltd bought a new position in Immatics during the 4th quarter valued at $211,000. Platinum Investment Management Ltd. increased its position in shares of Immatics by 53.1% during the 4th quarter. Platinum Investment Management Ltd. now owns 311,722 shares of the company’s stock valued at $2,216,000 after purchasing an additional 108,108 shares during the period. Finally, Mitsubishi UFJ Asset Management Co. Ltd. raised its stake in shares of Immatics by 24.6% in the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 22,701 shares of the company’s stock worth $163,000 after buying an additional 4,477 shares in the last quarter. Institutional investors own 64.41% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Immatics in a research note on Tuesday, April 1st. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Immatics currently has a consensus rating of “Buy” and a consensus price target of $16.67.

Immatics Stock Performance

NASDAQ IMTX opened at $4.52 on Friday. Immatics has a 1 year low of $3.30 and a 1 year high of $13.77. The business’s fifty day moving average is $4.42 and its two-hundred day moving average is $6.37. The stock has a market capitalization of $549.41 million, a P/E ratio of -6.85 and a beta of 0.85.

Immatics (NASDAQ:IMTX) last announced its earnings results on Thursday, March 27th. The company reported $0.48 EPS for the quarter, beating the consensus estimate of ($0.03) by $0.51. The business had revenue of $15.67 million during the quarter, compared to the consensus estimate of $16.16 million. Immatics had a negative return on equity of 15.90% and a negative net margin of 47.94%. On average, research analysts forecast that Immatics will post -0.72 earnings per share for the current year.

Immatics Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.